Physician profile
Alison E Oakes
NPI 1639460470
$7,426.57
in general payments reported to CMS, 2019-2025
37 companies · $968 in 2025
The $968 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,418 · 2020: $647 · 2021: $1,512 · 2022: $1,055 · 2023: $1,040 · 2024: $787 · 2025: $968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,794.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,794.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,494.41 | 2019-2025 | |
| Janssen Biotech, INC. | $596.36 | 2019-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $379.70 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $339.37 | 2019-2024 | Trulance, Xifaxan |
| Pfizer INC. | $332.15 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $285.40 | 2019-2025 | Entyvio |
| Nestle Healthcare Nutrition INC. | $265.01 | 2020-2023 | |
| Aimmune Therapeutics, INC. | $194.51 | 2024-2025 | Zenpep |
| Qol Medical, LLC | $177.81 | 2019-2023 | Sucraid |
| Celgene Corporation | $169.25 | 2022-2024 | Zeposia |
| Redhill Biopharma INC. | $156.71 | 2020-2022 | |
| Allergan, INC. | $145.71 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $106.72 | 2019-2023 | Ocaliva |
| Ardelyx, INC. | $93.79 | 2022-2025 | Ibsrela |
| Dynavax Technologies Corporation | $79.74 | 2019-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $75.54 | 2023-2025 | |
| Braintree Laboratories, INC. | $65.68 | 2020-2023 | Suflave |
| Madrigal Pharmaceuticals | $56.04 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $40.68 | 2024 | Dupixent |
| Rgh Enterprises LLC | $37.61 | 2025 | |
| Phathom Pharmaceuticals, INC. | $32.37 | 2024-2025 | Voquezna |
| Lucid Diagnostics INC. | $30.85 | 2022-2023 | |
| Ferring Pharmaceuticals INC. | $26.53 | 2021 | |
| Therapeuticsmd, INC. | $25.27 | 2020 | |
| Biocompatibles, INC. | $21.07 | 2019 | |
| Welch Allyn | $19.16 | 2021 | |
| Idorsia Pharmaceuticals US INC | $18.80 | 2022 | |
| Ucb, INC. | $17.63 | 2019 | |
| Biocon Biologics INC | $17.39 | 2025 | Yesintek |
| Shield Therapeutics INC | $16.69 | 2024 | |
| Daiichi Sankyo INC. | $16.51 | 2020 | |
| Echosens North America, INC. | $16.00 | 2025 | Fibroscan |
| Coloplast Corp | $15.83 | 2022 | |
| Novo Nordisk INC | $15.41 | 2025 | Wegovy |
| Sandoz INC. | $15.38 | 2024 | Hyrimoz |
| Merck Sharp & Dohme LLC | $14.89 | 2021 | |
| Alfasigma USA, INC. | $14.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Oakes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.